Interestingly, aberrantly high levels of EVI1 have also been observed across a range of non-hematologic malignancies including ovarian cancer,43,44 breast cancer,45 pancreatic cancer,46 colorectal cancer,47 and prostate cancer.48 While transcription factors like EVI1 might have cell type-specific targets and functions resulting from a context-dependent remodeling of the epigenetic landscape and gene expression, it would be of interest to investigate the commonalities in the mechanism of action of EVI1 across these diverse cancer entities. Here, RUNX1 is linked to prostate carcinoma.